AC
MBX

AXQ Capital’s MBX Biosciences MBX Stock Holding History

AXQ Capital’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$428K Buy
+7,757
New +$271K 0.05% 524
2026
Q1 		– Sell
-6,463
Closed -$204K – 1312
2025
Q4 		$204K Buy
+6,463
New +$157K 0.05% 564

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

AXQ Capital's MBX Position: Q2 2026 in Review

AXQ Capital opened a new position in MBX Biosciences (MBX) in Q2 2026: 7,757 shares worth $428K. The stake represents 0.05% of the portfolio and ranks #524 among its holdings. This is a return to the name: AXQ Capital previously reported a position in MBX as recently as Q4 2025.

AXQ Capital first reported a position in MBX in Q4 2025 and has held it in 2 quarters since. 173 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • AXQ Capital held 7,757 shares of MBX Biosciences worth $428K as of Q2 2026.
  • MBX Biosciences was a new AXQ Capital position in Q2 2026.
  • MBX Biosciences made up 0.05% of AXQ Capital's portfolio in Q2 2026, its #524 holding.
  • AXQ Capital first reported a position in MBX Biosciences in Q4 2025 and has held it in 2 quarters since.
  • 173 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.